28
total announcements
GUFICBIO.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹4,056 Cr
P/E (TTM)
55.3
EPS (TTM)
₹7.32
52W Low
₹268.00
52W High
₹467.80
Dividend Yield
0.02%
Beta
-0.03
Price / Book
6.1
Debt / Equity
60.9
Revenue (TTM)
₹981 Cr
Gross Margin
54.77%
Operating Margin
14.92%
Gufic Biosciences Limited
Gufic Biosciences Limited has informed the Exchange about a newspaper advertisement regarding a special window for re-lodgement of transfer and dematerialization of physical shares, as per SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026.
Gufic Biosciences Limited
Gufic Biosciences Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing on stock exchanges.
Gufic Biosciences Limited
Gufic Biosciences Limited has received an appellate order in favor of the company, allowing the appeal against an income tax demand of Rs. 4,33,36,680 for the Assessment Year 2024-25.
Gufic Biosciences Limited
Gufic Biosciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Gufic Biosciences Limited
Gufic Biosciences Limited has informed the Exchange about Intimation of Environmental, Social and Governance (ESG) Rating. Crisil ESG Ratings & Analytics Ltd has assigned an overall ESG rating of CRISIL ESG 62 (Category: Strong) to the Company for FY 2025-26.
Gufic Biosciences Limited
Gufic Biosciences Limited has informed the Exchange about Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding penalties levied by BSE and NSE for non-compliance with the provisions of Regulation 17(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, pertaining to the appointment of an Additional Director. The Company has filed Waiver Applications with BSE and NSE, but both have been rejected. The penalty of ₹1,72,000/- (excluding GST) levied by NSE for the quarter ended September 30, 2024 is required to be paid on or before October 03, 2026.
Gufic Biosciences Limited
Gufic Biosciences Limited has informed the Exchange that its credit ratings have been reaffirmed by Crisil Ratings Limited.
Gufic Biosciences Limited
Gufic Biosciences Limited has announced the voting results of its 42nd Annual General Meeting (AGM) held on September 4, 2026, where all resolutions were passed with high voting percentages. The company declared a final dividend of 10% for the financial year ended March 31, 2026, and appointed a new director in place of Mr. Pranav J. Choksi.
Gufic Biosciences Limited
Gufic Biosciences Limited has informed the Exchange regarding Proceedings of 42nd Annual General Meeting held on September 04, 2026
Gufic Biosciences Limited
Gufic Biosciences Limited has informed the Exchange about the promotion and change in designation of two senior management personnel, Ms. Ami Shah as Head-Legal and Mr. Pinak Padhya as President – Sales & Marketing, effective September 02, 2026.
Gufic Biosciences Limited
Gufic Biosciences Limited has informed the Exchange about the written transcript of the Earnings Conference Call held on August 17, 2026, for Q1 FY27.
Gufic Biosciences Limited
Gufic Biosciences Limited has informed the Exchange about a Special Window for Re-lodgement of Transfer and Dematerialization of Physical Shares, as per SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026.
Gufic Biosciences Limited
Gufic Biosciences Limited has uploaded the audio recording of its earnings conference call on its website, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Gufic Biosciences Limited
Gufic Biosciences Limited has published unaudited financial results for the quarter ended June 30, 2026, in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Gufic Biosciences Limited
Gufic Biosciences Limited has submitted its Investor Presentation for Q1FY2027, highlighting its advanced lyophilized injectable facility, production milestones, and future plans for capacity expansion and product launches.
Gufic Biosciences Limited
Gufic Biosciences Limited has informed the Exchange about the approval of the incorporation of a subsidiary in the Philippines and investment by way of subscription to its equity share capital.
Gufic Biosciences Limited
Gufic Biosciences Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, along with the approval of incorporating a subsidiary in the Philippines and investing in its equity share capital. The company has also disclosed its unaudited financial results, which show a revenue of ₹26,122.75 lakhs and an expense of ₹10,611.42 lakhs.
Gufic Biosciences Limited
Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Publication of Notice of 42nd Annual General Meeting of the Company and e-voting details.
Gufic Biosciences Limited
Gufic Biosciences Limited has announced the record date for its 42nd Annual General Meeting (AGM) and dividend payment. The record date is August 28, 2026, and the AGM will be held on September 4, 2026. The company will close its register of members and share transfer books from August 29 to September 4, 2026, for the purpose of the AGM and dividend payment.
Gufic Biosciences Limited
Gufic Biosciences Limited has informed the Exchange regarding Notice of 42nd Annual General Meeting to be held on September 04, 2026, with the Register of Members and Share Transfer Books closed from August 29, 2026 to September 04, 2026 for the purpose of AGM and payment of final dividend.